Business
CORRECTING and REPLACING – European High Growth Opportunities Securitization Fund Converts Debentures of Alternate Health Corp.
CORRECTING and REPLACING – European High Growth Opportunities Securitization Fund Converts Debentures of Alternate Health Corp..
About this update from Alternate Health Corp
[{"type":"text","content":"\n In a release issued under the same headline on September 13, 2019 by European High Growth Opportunities Securitization Fund, please note that in the third paragraph of the release, the correct number of Common Shares is 8,936,484, not 67,752,095 Common Shares as previously stated. The corrected release follows: TORONTO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- European High Growth Opportunities Securitization Fund (the “Fund”) announced today the conversion of $300,000 of its aggregate $700,000 of Debentures (as defined below) of Alternate Health Corp. (“Alternate Health” or the \"Company\") (CSE:AHG) (OTCQB:AHGIF) between July 23, 2019 and September 3, 2019 (collectively, the “Conversions”) and the sale of an aggregate 1,645,111 Shares (as defined below) between July 12, 2019 and September 6, 2019. Pursuant to the terms of a financing arrangement (the “Financing”), the Company issued to the Fund a convertible debenture (the “Debenture”) in the principal aggregate amount of $700,000 and share purchase warrants (the “Warrants”) exercisable to acquire up to an aggregate of 3,348,484 common shares of the Company (the “Shares”). The Debenture and Warrants otherwise have the terms described in the Company’s press releases dated July 5, 2019 and July 17, 2019. Further terms of the Financing are set out in the Subscription Agreements as filed on SEDAR and available under the Company’s profile at www.sedar.com. Immediately following the closing of the Financing, the Acquiror owned, controlled or directed (directly or indirectly): (i) an aggregate principal amount of $700,000 Debentures; and (ii) 3,348,484 Warrants. Based on the foregoing, the Acquiror, directly or indirectly, beneficially owned or exercised control or direction over 8,936,484 Common Shares, representing approximately 13.19% of the issued and outstanding Common Shares on a non-diluted basis (assuming the conversion of the aggregate principal amount of $700,000 Debentures and the exercise of the 3,348,484 Warrants) and 12.14% of the issued and outstanding Common Shares on a diluted basis. After giving effect to the Conversions and the sale of Shares, the Acquiror owns, controls or directs (directly or indirectly): (i) an aggregate principal amoun...